TLR4

Overview

toll-like receptor 4 (TLR4) is a pattern recognition receptor belonging to the toll-like receptor (TLR) family, encoded by the TLR4 gene. It is a transmembrane glycoprotein constitutively expressed on the surface of innate immune cells — including monocytes, macrophages, dendritic cells, neutrophils, and microglia — as well as on a variety of non-immune cell types such as hepatic stellate cells and neurons. TLR4 is best characterized as the primary sensor for lipopolysaccharide (LPS), a structural component of gram-negative bacterial cell walls, but it also recognizes endogenous danger signals (damage-associated molecular patterns, or DAMPs) such as high-mobility group box 1 protein (HMGB1) and lumican. Upon ligand binding, TLR4 recruits the adapter protein myeloid differentiation primary response 88 (MyD88), initiating downstream signaling cascades that culminate in the activation of nuclear factor kappa B (NF-κB) and the production of proinflammatory cytokines including interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).

Beyond its canonical role in host defense against bacterial infection, TLR4 is increasingly recognized as a central mediator of sterile inflammation across a broad spectrum of pathological conditions. Its activation drives tissue-damaging neuroinflammation in neurodegenerative and neuropathic pain states, promotes fibrosis, facilitates tumor progression and metastasis, and modulates immunophenotypic changes in circulating leukocytes exposed to environmental or pharmacological stressors. This dual role — protective in acute infection yet injurious in chronic or dysregulated contexts — makes TLR4 a high-priority research target for therapeutic intervention in inflammation-driven diseases, ranging from metabolic dysfunction–associated steatotic liver disease (MAFLD/NAFLD) to Parkinson's disease and cancer.

Recent Publications Focus

Below is a summary of the newest research publications targeting TLR4 (sorted by publication date).

Recent studies have continued to position TLR4 as a central mediator of inflammatory and neuroimmune signaling across diverse disease models. In Parkinson's disease mice, astragaloside IV was reported to directly bind TLR4 and suppress TLR4/NF-κB signaling in microglia, improving both motor coordination and anxiety-like behaviors while reducing pro-inflammatory cytokines and preserving dopaminergic and hippocampal neurons. Importantly, these benefits were abolished in TLR4-deficient mice, supporting TLR4 as the essential target. In a rat model of desert dry-heat-induced exertional heat stroke, nanocurcumin was shown to attenuate brain injury, neuroendocrine dysfunction, and systemic inflammation, with dose-dependent inhibition of TLR4, MyD88, and NF-κB protein expression in brain tissue. Similarly, astaxanthin improved neurological deficits, brain edema, infarct volume, and apoptosis after ischemic stroke, and these protective effects were linked to inhibition of the TLR4 pathway and were reversed by the TLR4 agonist RS 09.

Several publications focused on TLR4 in inflammatory and fibrotic disorders. In rheumatoid arthritis, phenylpropanoids from Dendropanax proteus root extract were identified as anti-RA constituents that reduced TLR4 protein expression in TNF-α-stimulated MH7A cells and were proposed to act through the TLR4-COX-2 axis. In NAFLD, rutin was reported to alleviate steatosis, oxidative stress, mitochondrial dysfunction, and inflammatory cytokine production, while mechanistic work indicated that it directly binds RUNX1, disrupts the RUNX1/TET2 complex, and inhibits downstream TLR4/NF-κB signaling. In liver fibrosis, lumican was specifically highlighted as interacting with TLR4 to accelerate hepatic fibrosis by activating hepatic stellate cells, underscoring a pro-fibrotic role for TLR4-associated signaling.

TLR4 also appeared in studies of microglial immune regulation and broader inflammatory network analyses. A study of dually charged dendrimeric polyglycerol in human microglia verified binding of HMGB1 and IL-33 to ST2, RAGE, and TLR4, and showed that charge-dependent dendrimers could modulate these alarmin-receptor interactions. In Alzheimer's disease-related network pharmacology work, TLR4 was among the overlapping targets linking gut microbiota-derived metabolites to immune-inflammatory pathways, alongside IL6, NFKB1, IL1B, PTGS2, and PPARG, with enrichment in response to lipopolysaccharide, oxidative stress, apoptosis, and pathways including NF-κB, TNF, MAPK, and NOD-like receptor signaling. In lung adenocarcinoma, TLR4 was identified as one of six core PANoptosis-related genes enriched in M2 macrophages, with functional analyses implicating NF-κB and NOD-like receptor signaling and suggesting that ginsenosides may inhibit a TLR4/NLRP3 survival axis.

Other recent work reinforced TLR4’s role as a signaling node in neuroinflammation and immune activation. Liquiritin was proposed to attenuate trigeminal neuropathic pain via TLR4/MyD88-dependent modulation of microglial M1-like polarization. In a mucosal vaccination study, TLR4 ligands were combined with Toll-like receptor 7/8 ligands in an intranasal liposomal formulation that generated broad, durable protection in mice against respiratory threats including SARS-CoV-2 and Staphylococcus aureus, mediated by persistent memory T cells and trained alveolar macrophages. Together, these publications portray TLR4 as a recurring target in computational, cellular, and in vivo studies spanning neurodegeneration, stroke, heat injury, arthritis, fibrosis, cancer, and vaccine adjuvant design.

Background PMIDs

• [PMID 42183904]
• [PMID 42406171]

Method PMIDs

• [PMID 41962465]

Result PMIDs

• [PMID 41924844]
• [PMID 42166674]

Target PMIDs

• [PMID 41712698]
• [PMID 41846059]
• [PMID 41880679]
• [PMID 41924844]
• [PMID 41935997]
• [PMID 41955312]
• [PMID 41997405]
• [PMID 42043860]
• [PMID 42050264]
• [PMID 42081615]
• [PMID 42396648]
• [PMID 42406869]